153 related articles for article (PubMed ID: 31059070)
1. Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
Ota K; Okuma T; Lorenzo A; Yokota A; Hino H; Kazama H; Moriya S; Takano N; Hiramoto M; Miyazawa K
Oncol Rep; 2019 Jul; 42(1):231-242. PubMed ID: 31059070
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
3. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
[TBL] [Abstract][Full Text] [Related]
7. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
8. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells.
Ni J; Chen K; Zhang J; Zhang X
Biochem Biophys Res Commun; 2021 Aug; 567():154-160. PubMed ID: 34157442
[TBL] [Abstract][Full Text] [Related]
13. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
14. PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
Mittal S; Kamath A; Joseph AM; Rajala MS
Int J Oncol; 2020 Oct; 57(4):989-1000. PubMed ID: 32945365
[TBL] [Abstract][Full Text] [Related]
15. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
[TBL] [Abstract][Full Text] [Related]
16. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
[TBL] [Abstract][Full Text] [Related]
18. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
20. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Cheng C; Zhao Y; Schaafsma E; Weng YL; Amos C
Int J Cancer; 2020 Nov; 147(9):2621-2633. PubMed ID: 32406930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]